Tumor mutational burden (TMB), a biomarker used to assess whether a patient will respond to immunotherapy, needs to be recalculated in order to be useful for patients of Asian or African descent. Scientists at the Dana-Farber Cancer Institute found a significant bias in the estimated TMB values affecting these populations and adjusted them for those patients. Read More
Two new studies now have uncovered fungal DNA in tumors throughout the body and endeavor to characterize the cancer mycobiome. Both studies were published in the Sept. 29, 2022, online issue of Cell. Although the association between cancer and individual microbes has long been explored, recent attention has focused on the whole human microbiome. Read More
Prometheus Biosciences Inc. has received FDA clearance of its IND application to proceed with a phase I trial of PRA-052 for ulcerative colitis. Read More
Leucine-rich repeat kinase 2 (LRRK2) mutations adversely impair multiple physiological processes, and gain-of-function mutations in the LRRK2 gene are common in familial forms of Parkinson’s disease (PD). Read More
Beta Pharma Inc. has patented pyridopyrimidines acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Imunon Inc. has reported partial results from an ongoing nonhuman primate study designed to examine the immunogenicity of its proprietary Placcine vaccine (PL-COV). The data support Placcine as a viable alternative to mRNA vaccines. Read More
Infex Therapeutics Ltd. has divulged nonstructural protein 3 (nsp3, PL-PRO) macrodomain (Mac1) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome. Read More
For a long time, α2-adrenoceptor antagonists have been successfully used as adjunct therapy to improve pharmacotherapy of antipsychotics, antidepressants or anti-parkinsonian drugs. Read More
Tohoku University has divulged quinoline compounds acting as histamine N-methyltransferase (HNMT) inhibitors reported to be useful for the treatment of narcolepsy, Alzheimer's disease and attention deficit hyperactivity disorder (ADHD). Read More
Additional early-stage research and drug discovery news in brief, from: Applied DNA Sciences, Cardiol Therapeutics, SQZ Biotechnologies, Therapeutic Solutions International. Read More